
    
      To explore the safety and efficacy of Glumetinib combined with Osimertinib in the treatment
      of relapsed and metastatic non-small cell lung cancer (NSCLC) with failed first-generation or
      second-generation EGFR inhibitors, negative T790M mutation and met amplification.
    
  